Mylan N.V. (MYL) Shares Bought by Wells Fargo & Company MN
Wells Fargo & Company MN lifted its holdings in shares of Mylan N.V. (NASDAQ:MYL) by 153.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,480,609 shares of the company’s stock after acquiring an additional 896,513 shares during the quarter. Wells Fargo & Company MN owned approximately 0.28% of Mylan worth $46,447,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Bellwether Investment Group LLC lifted its holdings in Mylan by 0.3% during the 2nd quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock worth $257,000 after purchasing an additional 23 shares during the last quarter. Suntrust Banks Inc. lifted its holdings in Mylan by 0.7% during the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock worth $355,000 after purchasing an additional 60 shares during the last quarter. Dai Ichi Life Insurance Company Ltd lifted its holdings in Mylan by 0.4% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock worth $1,009,000 after purchasing an additional 107 shares during the last quarter. Wealthsource Partners LLC lifted its holdings in Mylan by 1.9% during the 2nd quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock worth $362,000 after purchasing an additional 177 shares during the last quarter. Finally, Accident Compensation Corp lifted its holdings in Mylan by 0.3% during the 2nd quarter. Accident Compensation Corp now owns 71,035 shares of the company’s stock worth $2,758,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 73.86% of the company’s stock.
Mylan N.V. (NASDAQ MYL) opened at $38.67 on Monday. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan N.V. has a fifty-two week low of $29.39 and a fifty-two week high of $45.87. The company has a market capitalization of $20,743.98, a price-to-earnings ratio of 8.23, a PEG ratio of 2.12 and a beta of 1.38.
Several analysts recently weighed in on MYL shares. Wells Fargo & Company set a $32.00 price target on Mylan and gave the stock a “hold” rating in a report on Wednesday, October 4th. Morgan Stanley lifted their price objective on Mylan from $36.00 to $39.00 and gave the company an “equal weight” rating in a report on Friday, October 6th. BidaskClub raised Mylan from a “hold” rating to a “buy” rating in a report on Friday, October 27th. BMO Capital Markets reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Mylan in a report on Friday, September 29th. Finally, ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $41.49.
WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/11/mylan-n-v-myl-shares-bought-by-wells-fargo-company-mn.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.